Mr. Geffen lamented the downsizing of the $500 million David Geffen Hall project at Lincoln Center. “New York should have the best of everything,” he said.
NYS Entity Status
NYS Filing Date
SEPTEMBER 13, 2013
NYS DOS ID#
NYS Entity Type
FOREIGN NOT-FOR-PROFIT CORPORATION
2013 - DAVID C COOK
Around the Web
- David Geffen Criticizes ‘Shameful’ Lack of Support for Concert Hall
By ROBIN POGREBIN and MICHAEL COOPER - Wednesday Oct 4, 2017
- Todd Frazier making case for NY return — but not with Yankees?
By Joel Sherman - Tuesday Oct 17, 2017
Todd Frazier was the third piece in a three-player package the Yankees received in July, present as much because the White Sox wanted to unload the rest of his salary as the Yankees hungered for his inclusion. Tommy Kahnle was priority one for the Yankees, David Robertson the second key, both made more attractive because...
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]
- Discovery cooks up a winning plan for Scripps
By Claire Atkinson - Tuesday Aug 1, 2017
John Malone’s Discovery Communications hooked a long-hunted prey on Monday, reeling in Scripps Networks Interactive for $14.6 billion. It is the third time that the David Zaslav-helmed Discovery has pursued the family-owned parent of the Food Network, HGTV and other cable outlets. Zaslav, 57, finally closed the deal by offering Scripps shareholders $90 per share,...
- “It’s Shame On Us If We Blow It”: Highlights From NY Seizes the Momentum
By Ben Fidler - Wednesday Jun 7, 2017
Mike Foley, a drug industry veteran and director of the Tri-Institutional Therapeutics Discovery Institute, has a pointed message for the New York life sciences industry: Don’t waste the moment. Changing the course of New York biotech has been a saga that dates back to the 1990s, and as Xconomy has detailed, progress has been made […]